These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33607781)

  • 1. Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis.
    Li B; Chen X; Ding T; Liu Y; Ma T; Zhang G; Wang X
    Medicine (Baltimore); 2021 Feb; 100(7):e24514. PubMed ID: 33607781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis.
    Li BX; Chen XJ; Ding TJ; Liu YH; Ma TT; Zhang GL; Wang XM
    J Cancer; 2021; 12(17):5164-5172. PubMed ID: 34335933
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.
    Yang M; Qu H; Liu A; Liu J; Sun P; Li H
    J Cancer Res Ther; 2019; 15(7):1561-1566. PubMed ID: 31939438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Futamura M; Oba M; Masuda N; Bando H; Okada M; Yamamoto Y; Kin T; Saeki T; Nagashima T; Kuwayama T; Toh U; Hirano A; Inokuchi M; Yamagami K; Mizuno Y; Kojima Y; Nakayama T; Yasojima H; Ohno S
    Breast Cancer; 2021 Sep; 28(5):1023-1037. PubMed ID: 33811599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
    Zong Y; Wu J; Shen K
    Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
    Lei L; Chen R; Fan L; Zheng W; Wang X
    Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Matsui A; Tatibana A; Suzuki N; Hirata M; Oishi Y; Hamaguchi Y; Murata Y; Nagayama A; Iwata Y; Okamoto Y
    Anticancer Res; 2017 Nov; 37(11):6481-6488. PubMed ID: 29061836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
    Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
    JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    He F; Liu J; Shen X; Wang Z; Li Q; Li G
    Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Liu M; Liu S; Yang L; Wang S
    BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
    Shizuku M; Shibata M; Shimizu Y; Takeuchi D; Mizuno Y
    Nagoya J Med Sci; 2020 Aug; 82(3):457-467. PubMed ID: 33132430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle Albumin‑Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.
    Gangannapalle M; Shahnoor H; Sattar L; Nagi TK; Al-Tekreeti M; Khan MW; Haseeb MD; Khan A
    Cureus; 2023 Jul; 15(7):e41711. PubMed ID: 37575705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
    Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
    Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models.
    Chen H; Huang S; Wang H; Chen X; Zhang H; Xu Y; Fan W; Pan Y; Wen Q; Lin Z; Wang X; Gu Y; Ding B; Chen J; Wu X
    Drug Deliv; 2021 Dec; 28(1):1067-1079. PubMed ID: 34109887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis.
    Lee H; Park S; Kang JE; Lee HM; Kim SA; Rhie SJ
    Sci Rep; 2020 Jan; 10(1):530. PubMed ID: 31953463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.